Table 7.

Data of the EGFR, Bcl2 and Casp3 Genes Expression in Human Colon Cancer (CACO-2) Cells Treated with Aqueous C. tiglium L. extract before and after Incorporating ZnO-NPs

Extract		EGFR
		Control cells			Test cells				FLD
	Conc. (µM)	GAPDH	EGFR	ΔCTC	GAPDH	EGFR	ΔCTE	ΔΔ CT	2 -ΔΔCT
		HC	TC	TC-HC	HE	TE	TE-HE	ΔCTE-ΔCTC	Eamp=1.849
Aqueous C. tiglium extract		23.46	26.82	3.36	24.08	27.86	3.78	0.42	0.77
ZnO-Aqueous nano-extract		23.46	26.82	3.36	23.82	28.55	4.73	1.37	0.43
Doxorubicin		23.46	26.82	3.36	23.91	29.21	5.3	1.94	0.30
Control		23.46	26.82	3.36	23.46	26.82	3.36	0.00	1.00
Extract		Bcl2
		Control cells			Test cells				FLD
	Conc. (µM)	GAPDH	Bcl2	ΔCTC	GAPDH	Bcl2	ΔCTE	ΔΔ CT	2 -ΔΔCT
		HC	TC	TC-HC	HE	TE	TE-HE	ΔCTE-ΔCTC	Eamp=1.849
Aqueous C. tiglium extract		23.46	28.76	5.30	24.08	30.15	6.07	0.77	0.62
ZnO-Aqueous nano-extract		23.46	28.76	5.30	23.82	30.58	6.76	1.46	0.41
Doxorubicin		23.46	28.76	5.30	23.91	30.83	6.92	1.62	0.37
Control		23.46	28.76	5.30	23.46	28.76	5.30	0.00	1.00
Extract		Casp3
		Control cells			Test cells				FLD
	Conc. (µM)	GAPDH	Casp3	ΔCTC	GAPDH	Casp3	ΔCTE	ΔΔ CT	2 -ΔΔCT
		HC	TC	TC-HC	HE	TE	TE-HE	ΔCTE-ΔCTC	Eamp=1.849
Aqueous C. tiglium extract		23.46	33.61	10.20	24.08	32.75	8.67	-1.48	2.48
ZnO-Aqueous nano-extract		23.46	33.61	10.20	23.82	31.62	7.80	-2.35	4.24
Doxorubicin		23.46	33.61	10.20	23.91	30.79	6.88	-3.27	7.46
Control		23.46	33.61	10.20	23.46	33.61	10.2	0.00	1.00